← All drugs Report issue

yzj-1139

Small moleculeexperimental

Clinical trial activity

9 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

6

Phase 2

3

Phase 3

2

Phase 4

0

Earliest trial started Dec 1, 2017 (NCT06673927)

Timeline

2010s

Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Jan 1, 2019
Earliest Phase 2 Sponsor(trial)

2020s

Jan 1, 2021
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Orexin receptorANTAGONIST
Orexin receptor antagonist
- Orexin receptor type 2 (HCRTR2) ↗
- Orexin receptor type 1 (HCRTR1) ↗
- Orexin receptor 1
- Orexin receptor 2

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06975514	Phase 3	Mar 25, 2025	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06680531	Phase 1	Aug 31, 2024	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06671470	Phase 1	Aug 22, 2024	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06671444	Phase 1	Jun 3, 2024	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06671509	Phase 1	Mar 22, 2024	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT05525637	Phase 3	Dec 17, 2021	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06680505	Phase 2	Aug 4, 2019	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06685341	Phase 1	Mar 7, 2019	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06673927	Phase 1	Dec 1, 2017	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	For profit	9	9	3	2017

1 organizations

Page 1 / 1